We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aegerion Pharmaceuticals, Inc. | NASDAQ:AEGR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.97 | 1.91 | 1.97 | 0 | 01:00:00 |
|
|
|
|
|
Delaware
|
|
001-34921
|
|
22-2960116
|
(State of Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
(1)
|
Agreement and Plan of Merger
: The stockholders voted to adopt the Agreement and Plan of Merger, dated as of June 14, 2016 (as amended, the “merger agreement”), by and among the Company, QLT Inc. (“QLT”) and Isotope Acquisition Corp., an indirect wholly-owned subsidiary of QLT (“MergerCo”). The merger agreement provides for the merger of MergerCo with and into the Company (the “merger”), with the Company surviving as an indirect wholly-owned subsidiary of QLT.
|
Votes For
|
|
Votes Against
|
|
Abstain
|
|
Broker Non-Votes
|
22,694,521
|
|
12,995
|
|
30,828
|
|
0
|
(2)
|
Advisory Vote on Executive Compensation
: The stockholders voted to approve, on an advisory, non-binding basis, specific compensatory arrangements between the Company and its named executive officers relating to the merger.
|
Votes For
|
|
Votes Against
|
|
Abstain
|
|
Broker Non-Votes
|
22,205,206
|
|
492,513
|
|
40,625
|
|
0
|
|
|
|
|
|
AEGERION PHARMACEUTICALS, INC.
|
||
|
|
|
|
|
By:
|
/s/ Benjamin Harshbarger
|
|
Date: November 7, 2016
|
|
Benjamin Harshbarger
|
|
|
|
General Counsel
|
|
1 Year Aegerion Pharmaceuticals, Inc. Chart |
1 Month Aegerion Pharmaceuticals, Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions